A Study of Telitacicept in Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- Registration Number
- NCT05680480
- Lead Sponsor
- RemeGen Co., Ltd.
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.
- Detailed Description
This is a phase 2, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of telitacicept versus placebo while taking standard of care (SOC) treatment in adult subjects with active proliferative lupus nephritis (LN).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 120
- Males or females aged 18-75 years of age, inclusive.
- Diagnosis of systemic lupus erythematosus according to American College of Rheumatology criteria (1997).
- Active, biopsy-proven proliferative lupus nephritis Class III or IV with/without the presence of Class V, or pure Class V according to the 2003 ISN/RPS classification. The renal biopsy must be performed within 1 year prior to the screening visit or during screening period. The biopsy report will be used to confirm subject eligibility.
- Positive serum antibody results, defined as positive anti-nuclear antibody (ANA) and/or a positive anti-dsDNA serum antibody based on the study's central laboratory results.
- Active renal disease at screening requiring induction therapy with high dose corticosteroids (HDCS) with mycophenolate mofetil (MMF) or other oral forms of mycophenolate.
- Induction therapy for active renal disease: HDCS with mycophenolate mofetil (MMF) or other oral forms of mycophenolate should be initiated within 60 days prior to or on Day 1 (baseline). Initiation of induction is when both HDCS and MMF have been started.
- Able to understand the requirements of the study and provide written informed consent.
Main
-
Known hypersensitivity or contraindication to any drug products they plan to receive (e.g., MMF, corticosteroids).
-
History of allergy to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.
-
Received any of the following therapies:
- Treatment with any B cell targeted therapy (e.g., rituximab), unless it can be shown that B cells have returned to baseline level or normal;
- Received tumor necrosis factor inhibitors, interleukin receptor blockers, or other small molecules or biologics (including Belimumab) during the 12 weeks prior to screening or the 5 half-lives of the drug, whichever is longer;
- Received any experimental drugs during the 12 weeks prior to screening or the 5 half-lives of the drug, whichever is longer;
- Received plasma separation or plasma exchange during the 6 weeks prior to screening;
- Subjects who required dialysis within 1 year prior to screening.
- Received a live vaccine or live-attenuated vaccine within 4 weeks prior to screening or expected to vaccinate during the study.
- Received BCG Vaccine within 1 year prior to screening.
-
History of severe active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis) requiring intervention within 60 days of baseline (Day 1).
-
History of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant or are due to receive transplantation.
-
Significant, unstable or uncontrolled acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy, or infectious diseases) which, in the opinion of the principal investigator, could confound the results of the study or put the subject at undue risk.
-
Plan to undergo surgery or have any medical disease, laboratory abnormality, or condition that, in the opinion of the principal investigator, makes the subject unsuitable for the study.
-
History of drug or alcohol abuse or dependence within 364 days prior to baseline (Day 1).
-
Nursing or pregnant female, or male or female who prepared for parenthood during the study.
-
History of malignant tumors within the last 5 years, excluding adequately treated skin cancer (basal or squamous cell) or carcinoma in situ of cervix.
-
Have acute or chronic infection requiring treatment.
-
HIV positive.
-
Hepatitis B: Patients positive for HBsAg are excluded; Patients negative for HBsAg but positive for Anti-HBc, regardless of Anti-HBs antibody status, will require test for HBV DNA: if HBV DNA positive, patients will be excluded; if HBV DNA negative, patients will be eligible to enroll.
-
Hepatitis C antibody positive.
-
History of COVID-19 within 4 weeks prior to screening or history of hospitalization due to severe Covid-19 within 12 months prior to screening.
-
eGFR<30 mL/min/1.73 m2 using CKD-EPI.
-
Renal biopsy showed 50% glomerulosclerosis.
-
Subjects who in the opinion of the investigator are not suitable to participate.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Telitacicept 160 mg Telitacicept 160 mg Telitacicept 160 mg given SC weekly plus standard therapy through week 48. Telitacicept 240 mg Telitacicept 240 mg Telitacicept 240 mg given SC weekly plus standard therapy through week 48. Placebo Placebo Placebo given SC weekly plus standard therapy through week 48.
- Primary Outcome Measures
Name Time Method Percentage of Participants with Complete Renal Response (CRR) Week 48 CRR is defined as estimated glomerular filtration rate (GFR) is no more than 20% below the baseline value or ≥ 60 mL/min/1.73m\^2 and 24-hour urinary protein: creatinine ratio ≤ 0.5 mg/mg and did not receive prohibited or rescue therapy resulting in treatment failure.
- Secondary Outcome Measures
Name Time Method Percentage of participants with Partial Renal Response (PRR) Week 24 and Week 48 PRR is defined as 24-hour urinary protein: creatinine ratio reduced by 50% compared to baseline value.
Incidence of AE, SAE Up to Week 48 An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A SAE is any untoward medical occurrence that at any dose resulting in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant and which the investigator regards as serious based on appropriate medical judgment.
Trial Locations
- Locations (45)
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, Guangdong, China
Affiliated Hospital of Hebei University
🇨🇳Baoding, Hebei, China
Peking University People's Hospital
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Liuzhou Workers' Hospital
🇨🇳Liuzhou, Guangxi, China
The Third Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Guizhou Provincial People's Hospital
🇨🇳Guiyang, Guizhou, China
Handan First Hospital
🇨🇳Handan, Hebei, China
Hebei General Hospital
🇨🇳Shijiazhuang, Hebei, China
The Third Affiliated Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, Henan, China
Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
🇨🇳Baotou, Inner Mongolia, China
Wuxi People's Hospital
🇨🇳Wuxi, Jiangsu, China
Zhongda Hospital Southeast University
🇨🇳Nanjing, Jiangsu, China
The First Hospital of Jilin University
🇨🇳Chang chun, Jilin, China
The Second Hospital of Jilin University
🇨🇳Changchun, Jilin, China
Shengjing Hospital of China Medical University
🇨🇳Shenyang, Liaoning, China
The Affiliated Hospital of Qinghai University
🇨🇳Xining, Qinghai, China
Qilu Hospital of Shandong University
🇨🇳Jinan, Shandong, China
Second Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
The Affiliated Hospital of Qingdao University
🇨🇳Qingdao, Shandong, China
Second Hospital of Shanxi Medical University
🇨🇳Taiyuan, Shanxi, China
Huashan Hospital Affiliated to Fudan University
🇨🇳Shanghai, Shanghai, China
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, Shanghai, China
Shanxi Provincial People's Hospital
🇨🇳Taiyuan, Shanxi, China
Shanxi Bethune Hospital
🇨🇳Taiyuan, Shanxi, China
West China Hospital Sichuan University
🇨🇳Chengdu, Sichuan, China
People's Hospital of Sichuan Province
🇨🇳Chengdu, Sichuan, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, Tianjin, China
Tianjin Medical University Second Hospital
🇨🇳Tianjin, Tianjin, China
The First Affiliated Hospital of Xinjiang Medical University
🇨🇳Urumqi, Xinjiang, China
The First Affiliated Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province
🇨🇳Linhai, Zhejiang, China
The Fourth Affiliated Hospital, Zhejiang University School of Medicine
🇨🇳Yiwu, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
🇨🇳Hefei, Anhui, China
The First Hospital Affiliated to the Army Medical University
🇨🇳Chongqing, Chongqing, China
The First Affiliated Hospital of Xiamen University
🇨🇳Xiamen, Fujian, China
Zhongshan Hospital Affiliated to Xiamen University
🇨🇳Xiamen, Fujian, China
The Third Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
Jiangxi Provincial People's Hospital
🇨🇳Nanchang, Jiangxi, China
General Hospital of Northern Theater Command of the Chinese People's Liberation Army
🇨🇳Shenyang, Liaoning, China
People's Hospital of Xinjiang Uygur Autonomous Region
🇨🇳Urumqi, Xinjiang, China
Zhejiang Provincial People's Hospital
🇨🇳Hangzhou, Zhejiang, China